The biotech company’s shares bolted today on good news out of its current trial. Here’s a closer look.
The post Why the Noxopharm share price rocketed 22% today appeared first on The Motley Fool Australia. –
The Noxopharm Ltd (ASX: NOX) share price went gangbusters today after the company released a new report about its flagship drug, Veyonda. Shares in the biotech closed trade 22% higher at 74 cents a share.
Lets take a closer look at what propelled the Noxopharm share price higher.
Noxopharm shares shot up today on the news that a new independent trial supports the use of Veyonda as a new anti-cancer drug.
Promisingly, the company advised that the combination of Veyonda and Lu-PSMA delivered a median overall survival outcome of 19.7 months, which inferred a 71% increase in survival outcome over an earlier study known as the WARMTH trial.
Also of note is that the study has helped Noxopharm validate that a higher dosage of the drug is well tolerated for a greater anti-cancer effect.
The LuPIN study will not formally conclude until October 2021 when the final data will be announced. As a result of the positive news announced today, the company also announced the possibility of a larger Phase 2 LuPIN study.
Dr Graham Kelly, Noxopharm CEO and managing director, welcomed the news:
This result further supports the Company’s belief that Veyonda has the potential to become a standard of care drug to be used in combination with the most common forms of anti-cancer treatments.
Based on early data from our CEP-1 and DARRT-1 clinical studies, we believe that the unique multiple anti-cancer actions of Veyonda have the potential to produce meaningful survival benefits as a combination treatment across multiple treatment combinations. The striking difference in mOS outcomes between the LuPIN and WARMTH trialsserves to further support that belief.
About the Noxopharm share price
Noxopharm is an Australian clinical stage drug development company focused on the treatment of cancer.
The Noxopharm share price is up an impressive 250% over the last year. Far eclipsing the 24.7% return of the All Ordinaries Index (ASX: XAO).
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of May 24th 2021